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Multivessel revascularisation in
ST-elevation myocardial
infarction: too early to change the
guidelines
To the Editor: With great interest we have
read the article by Politi et al1 on revascu-
larisation of patients with ST-elevation
myocardial infarction and multivessel
disease. The authors are to be complimented
on the largest randomised trial on this
subject, with the longest follow-up.
However, we question whether this study
is the ‘justiﬁcation for complete revascular-
isation at the time of primary angioplasty ’,
as the paper is labelled by the accompanying
editorial. Apart from the considerable
imbalance in patient numbers, which
remains unexplained, there are several other
major concerns.
First, there is no mention of routine non-
invasive testing for ischaemia after discharge
in the culprit-only revascularisation (COR)
group, as is currently advocated by the
guidelines.2 It is thus not clear if the additional
percutaneous coronary intervention proce-
dures in the COR group were unexpected
events or a result of planned non-invasive
testing. All these events were considered
major adverse cardiac events in the COR
group,while planned revascularisations in the
staged revascularisation (SR) group were not.
Second, testing for ischaemia is relevant
because 40% of non-culprit lesions do not
produce ischaemia, as we demonstrated in
a recent randomised trial of fractional ﬂow
reserve-guided early (7.5 days) additional
revascularisation compared with COR.3 Also,
we found that after 6 months death and
myocardial infarction had occurred only in
the early treatment group. This underlines
that early additional treatment is probably
not without risk, while beneﬁt is not to be
expected in a considerable number of patients.
Third, the importance of complete revascu-
larisation is emphasised in the discussion, but it
is not clear in how many patients of the
complete revascularisation or SR group this
was actually achieved.Asmorecomplex lesions
are to be expected in a population with multi-
vessel disease, in which for instance approxi-
mately 30%of the patients have a chronic total
occlusion, this is a relevantquestion. It hasbeen
suggested that the presence of a chronic total
occlusion is the only independent factor that
determines the additional risk in patients with
multivessel disease.4
For now, it seems that staged percutaneous
coronary intervention of non-culprit lesions
guided by ischaemia testing is still the most
reasonable treatment strategy for patients
with multivessel disease and ST-elevation
myocardial infarction. We agree with the
authors thatmore research is clearly needed to
deﬁne the optimal treatment in thesepatients.
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Multivessel revascularisation in
ST-elevation myocardial
infarction: too early to change the
guidelines
The Authors’ reply: We thank Drs
Dambrink and Van ’t Hof1 for their interest in
our publication.2 This study showed that in
the setting of primary angioplasty, patients
with multivessel coronary disease treated
with complete revascularisation during the
index or staged procedure have a reduced rate
of long-term major adverse coronary events.
In the accompanying editorial,3 Drs Malik
and Gerber appoint this study as the ‘justiﬁ-
cation for complete revascularisation at the
time of primary angioplasty ’. Indeed, this is
the largest randomised trial supporting the
results of recent non-randomised or smaller
studies that described more beneﬁts with an
aggressive rather than a conservative
approach in patients with ST-elevation
myocardial infarction (STEMI) and diffuse
coronary disease.4 5
We are pleased to have the opportunity to
clarify some issues that, due to word count
restrictions, might not have been sufﬁciently
detailed.
As stated in our paper, except the planned
procedures in the staged revascularisation
(SR) group, all additional percutaneous coro-
nary interventions (PCI) were unexpected
procedures driven by recurrent symptoms, re-
infarction or evidence of signiﬁcant ischaemia
on provocative testing. Nevertheless, exercise
testing was not routinely planned, but it was
performed only in the case of dubious symp-
toms at the clinical examination. By study
protocol, patients were all discharged on
maximal anti-ischaemic therapy and
followed by clinical periodical visits. Of note,
current guidelines6 do not advocate, rather
simply judge ‘appropriate’, outpatient exer-
cise testing (bicycle or treadmill) or stress
imaging (using scintigraphy, echocardiog-
raphy, or MRI) within 4e6 weeks of STEMI.
Furthermore, the guidelines underscore that
the ‘relative advantages or disadvantages of
these stress tests in a post-STEMI population
are not well established’.
The authors quote their recent randomised
trial7 showing that 6 month death and
myocardial infarction occurred only in
patients with additional (fractional ﬂow
reserve-guided) treatment of non-culprit
lesions. This result led them to conclude that
the conservative strategy of treating the
infarct related artery (IRA) only could avoid
the complications arising from repeat proce-
dures, but the majority of infarctions in the
invasive group (6/11) occurred before frac-
tional ﬂow reserve and then are not a conse-
quence of new PCI. In our population SR and
complete revascularisation (CR) strategies
were safer than culprit-only revascularisation,
which showed a higher mortality, even if not
signiﬁcantly different. We explained this
possible protective effect of complete PCI by
an effect of stilling other potentially unstable
plaques. Indeed, the inﬂammatory reaction
arising during acute coronary syndromes and
responsible for plaque instability is not
limited to the culprit lesion, but involves the
entire coronary tree.8
Both the SR and CR group received
a complete revascularisation but at different
times: in the CR group at the time of
primary angioplasty, whereas in the SR
group during the planned procedure (ie, after
a mean of 57 days). We agree that chronic
total occlusion (CTO) represents an inde-
pendent additional risk factor in patients
with multivessel disease. We examined our
population and no patients had CTO, prob-
ably because subjects with concurrent
STEMI and CTO often develop haemody-
namic instability or shock, which were
exclusion criteria of the study.
Our study shows that patients with
STEMI and 70e99% diameter stenosis of
non-culprit coronary arteries have a high-risk
proﬁle such that a conservative strategy may
be unsafe, thus complete early or subacute
revascularisation should be considered.
Finally, we agree with the authors that it
may be too early to change the guidelines;
however, our study represents the ﬁrst stone
for building new evidence for the treatment
of STEMI in the setting of multivessel
disease and encourages further research
before changing the recommendations in
this ﬁeld.
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Long-term dual antiplatelet
therapy after percutaneous
coronary intervention
To the Editor: The statistics of propensity
adjustment which Harjai et al1 have used
with some modiﬁcations is a recognised tool
to increase the value of non-experimental
data.2 3 However, these authors have used
propensity statistics less efﬁciently than
other studies in this area.2 3 In fact,
propensity statistics have only been intro-
duced by Harjai et al in their multivariate
regression analysis, but no 1:1 propensity
matching has been made to identify two
patient subgroups of identical size (derived
from the cohorts who continued or discon-
tinued the treatment, respectively) or to
compare outcomes between these two
matched pair subgroups.
No speciﬁc rules have yet been devised to
determine the size of the cohorts to be
included in propensity analyses. Nonethe-
less, since propensity studies have less
quality of evidence than randomised studies,
one can reasonably assume that the number
of patients included in propensity studies
should not be smaller than the number of
patients one would include in a randomised
study aimed at the same question.
In patients receiving percutaneous coro-
nary intervention, the opportunity to
continue clopidogrel at 6 or 12 months is
presently a matter of debate. Using non-
inferiority power calculations (power¼0.80,
a¼0.05, event frequency around 10%, clini-
cally meaningful RR reduction set at 20%),
a total of at least 2500 patients (1250 per
arm) would be needed to adequately power
a randomised study. Event frequencies of
<10% would give even larger sample sizes.
Two propensity analyses have recently
addressed this issue.1 4 The study by Harjai
et al1 analysed 835 patients treated with bare
metal stents and 1024 treated with drug-
eluting stents, while Shin et al4 examined
fewer patients (N¼844) treated with drug
eluting stents (with the advantage that
a matched-pair analysis was tried). Both
studies suggest that prolonging clopidogrel
beyond 6 or 12 months confers no beneﬁt.
Although these ﬁndings have been inter-
preted in this way, it has not been observed
that these studies were largely underpow-
ered to adequately address this therapeutic
problem. Hence, a large-scale randomised
study is still needed in this area. Alterna-
tively, a propensity score investigation could
be useful provided that at least 3000 patients
are included in the matched pair analysis.
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Long-term dual antiplatelet
therapy after percutaneous
coronary intervention
The Authors’ reply: There are two
different approaches to using the propensity
score in statistical analyses. The ﬁrst
method, propensity score-adjusted multi-
variate analysis, involves the use of the
propensity score as a covariate in the multi-
variable analysis. This is the method we used
in our study. The second method, called
propensity matching, entails the inclusion of
only those subjects with similar propensity
scores. Propensity matching limits the total
number of patients that can be included in
the analysis. We therefore chose to use
propensity-adjusted multivariate analysis.1
We agree with Andrea Messori et al2 that
our study may not be adequately powered to
evaluate small differences in outcomes
between patient groups, and that large-scale
randomised clinical studies are the best way
to deﬁne the optimal duration of dual
antiplatelet therapy.
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